Unknown

Dataset Information

0

Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.


ABSTRACT: Purpose: A phase I trial of veliparib in combination with topotecan plus carboplatin (T+C) demonstrated a 33% objective response rate in patients with hematological malignancies. The objective is to perform exposure-response analysis to inform the phase II trial design.Experimental Design: Pharmacokinetic, efficacy, and safety data from 95 patients, who were administered 10 to 100 mg b.i.d. doses of veliparib for either 8, 14, or 21 days with T+C, were utilized for exposure-efficacy (objective response and overall survival) and exposure-safety (?grade 3 mucositis) analysis. Multivariate cox proportional hazards and logistic regression analyses were conducted. The covariates evaluated were disease status, duration of treatment, and number of prior therapies.Results: The odds of having objective response were 1.08-fold with 1,000 ng/hr/mL increase in AUC, 1.8-fold with >8 days treatment, 2.8-fold in patients with myeloproliferative neoplasms (MPN), and 0.5-fold with ?2 prior therapies. Based on analysis of overall survival, hazard of death decreased by 1.5% for 1,000 ng/hr/mL increase in AUC, 39% with >8 days treatment, 44% in patients with MPN, while increased by 19% with ?2 prior therapies. The odds of having ?grade 3 mucositis increased by 29% with 1,000 ng.h/mL increase in AUC.Conclusions: Despite shallow exposure-efficacy relationship, doses lower than 80 mg do not exceed veliparib single agent preclinical IC50 Shallow exposure-mucositis relationship also supports the 80-mg dose. Based on benefit/risk assessment, veliparib at a dose of 80 mg b.i.d. for at least 14 days in combination with T+C is recommended to be studied in MPN patients. Clin Cancer Res; 23(21); 6421-9. ©2017 AACR.

SUBMITTER: Mehrotra S 

PROVIDER: S-EPMC5837045 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.

Mehrotra Shailly S   Gopalakrishnan Mathangi M   Gobburu Jogarao J   Ji Jiuping J   Greer Jacqueline M JM   Piekarz Richard R   Karp Judith E JE   Pratz Keith W KW   Rudek Michelle A MA  

Clinical cancer research : an official journal of the American Association for Cancer Research 20170727 21


<b>Purpose:</b> A phase I trial of veliparib in combination with topotecan plus carboplatin (T+C) demonstrated a 33% objective response rate in patients with hematological malignancies. The objective is to perform exposure-response analysis to inform the phase II trial design.<b>Experimental Design:</b> Pharmacokinetic, efficacy, and safety data from 95 patients, who were administered 10 to 100 mg b.i.d. doses of veliparib for either 8, 14, or 21 days with T+C, were utilized for exposure-efficac  ...[more]

Similar Datasets

2022-09-08 | GSE192453 | GEO
| S-EPMC3689050 | biostudies-literature
| S-EPMC4520642 | biostudies-literature
| S-EPMC4612326 | biostudies-literature
| S-EPMC5543458 | biostudies-other
| S-EPMC3862960 | biostudies-literature
| S-EPMC6085179 | biostudies-literature
| S-EPMC10807611 | biostudies-literature
| S-EPMC2741047 | biostudies-other
| S-EPMC3108904 | biostudies-literature